Macquarie Group LTD Fibrogen Inc Transaction History

Macquarie Group LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$0.89 - $2.36 $4,135 - $10,966	4,647 New	4,647 $4,000
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $11,400 - $14,600	-1,000 Reduced 37.89%	1,639 $34,000
Q1 2021 May 14, 2021	BUY	$31.0 - $55.72 $10,447 - $18,777	337 Added 14.64%	2,639 $92,000
Q2 2020 Aug 11, 2020	BUY	$32.57 - $42.83 $12,278 - $16,146	377 Added 19.58%	2,302 $93,000
Q4 2019 Feb 14, 2020	SELL	$34.58 - $48.06 $57,921 - $80,500	-1,675 Reduced 46.53%	1,925 $83,000
Q3 2019 Nov 14, 2019	BUY	$36.98 - $48.45 $133,128 - $174,420	3,600 New	3,600 $133,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.